Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2003 Sep 15;13(18):2955-60.

Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: identification and optimisation of substituted 4,6-bis anilino pyrimidines.

Author information

1
AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.

Abstract

Using a high-throughput screening campaign, we identified the 4,6-bis anilino pyrimidines as inhibitors of the cyclin-dependent kinase, CDK4. Herein we describe the further chemical modification and use of X-ray crystallography to develop potent and selective in vitro inhibitors of CDK4.

PMID:
12941311
DOI:
10.1016/s0960-894x(03)00202-6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center